Drug Profile
Research programme: interleukin-2 mimetic peptide - AplaGen
Alternative Names: AGIL2-03; Research programme: IL2 mimetic peptide - AplaGenLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator AplaGen
- Class
- Mechanism of Action Interleukin 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Germany (Parenteral)
- 30 Jan 2007 This programme is still in active development for cancer in Germany
- 30 Nov 2005 Preclinical trials in Cancer in Germany (unspecified route)